Wednesday September 20th 2017

Shorter Washout Better for Natalizumab-to-Fingolimod Switch Shorter Washout Better for Natalizumab-to-Fingolimod Switch

A new study further confirms that upon switching from natalizumab to fingolimod in patients with multiple sclerosis, the washout period should be less than 3 months. Medscape Medical News (Source: Medscape Today Headlines)

Link: 

Shorter Washout Better for Natalizumab-to-Fingolimod Switch Shorter Washout Better for Natalizumab-to-Fingolimod Switch

Leave a Comment

More from category

New man-made antioxidant could help improve success rates of cell-based therapies
New man-made antioxidant could help improve success rates of cell-based therapies

Cell therapies being developed to treat a range of conditions could be improved by a chemical compound that aids their [Read More]

Patient and Provider Organizations Oppose Graham-Cassidy Health Care Proposal
Patient and Provider Organizations Oppose Graham-Cassidy Health Care Proposal

/About-the-Society/News/Patient-and-Provider-Organizations-Oppose-Graham-C [Read More]

Researchers Discover Potential Driver of MS Disease Progression and Test Ways to Block It
Researchers Discover Potential Driver of MS Disease Progression and Test Ways to Block It

/About-the-Society/News/Researchers-Discover-Potential-Driver-of-MS-Diseas [Read More]

Scientists discover markers for progressive multiple sclerosis
Scientists discover markers for progressive multiple sclerosis

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- [Read More]

Study uncovers markers for severe form of multiple sclerosis
Study uncovers markers for severe form of multiple sclerosis

Scientists have uncovered two molecules involved in cell communication and movement that may explain why some people [Read More]